Moreover, now that a phase III clinical trial (PLEO-CMT) is available for CMT patients with a specific mutation (PMP22 duplication, CMT1A) [50], the necessity of reaching a genetic definition for most of the patients is even greater, as it may make them eligible for future experimentations. Here, PMP22 is linked to Charcot-Marie-Tooth disease.